NCT04922593 - Relative Bioavailability of LY03010 Compared to Listed Drug | Biotech Hunter

Enrollment

281

Participants

Timeline

Start Date

January 13, 2021

Primary Completion Date

March 15, 2022

Study Completion Date

April 15, 2022

Conditions

SchizophreniaPsychotic DisordersMood DisordersSchizophrenia SpectrumMental DisordersAntipsychotic AgentsTranquilizing AgentsCentral Nervous System DepressantsPhysiological Effects of DrugsPsychotropic DrugsNeurotransmitter AgentsMolecular Mechanisms of Pharmacological Action

Interventions

DRUG

LY03010; paliperidone palmitate

LY03010 is white to off-white sterile aqueous extended-release suspension of paliperidone palmitate for IM injection.

DRUG

INVEGA SUSTENNA

INVEGA SUSTENNA (234 mg, 156 mg) is manufactured by Janssen Pharmaceuticals, Inc and is commercially available.

Trial Locations (9)

33016

Innovative Clinical Research, Inc., Miami Lakes

60640

Uptown Research Institute, LLC, Chicago

75080

Pillar Clinical Research, LLC, Richardson

75115

InSite Clinical Research, LLC, DeSoto

90502

CNS Network, LLC, Torrance

91945

Synergy San Diego, Lemon Grove

92845

Collaborative Neuroscience Network, Inc., Garden Grove

08009

Hassman Research Institute, Berlin

08053

Hassman Research Institute, Marlton

All Listed Sponsors

lead

Luye Pharma Group Ltd.

INDUSTRY